Table 3.
Therapy received during follow-up in relation to pathological features
| %RASB (>6months) | P-value | % Immuno- Suppression | P-value | |
|---|---|---|---|---|
| Mesangial hypercellularity score (M) | ||||
| ≤0.5 |
64 |
0.04 |
50 |
0.07 |
| >0.5 |
78 |
64 |
||
| Endocapillary proliferation (E) | ||||
| Absent |
69 |
0.6 |
54 |
0.4 |
| Present |
75 |
63 |
||
| Segmental glomerulosclerosis (S-alone) | ||||
| Absent |
59 |
<0.001 |
53 |
0.5 |
| Present |
83 |
59 |
||
| Segmental glomerulosclerosis or adhesion (S) | ||||
| Absent |
57 |
0.001 |
59 |
0.5 |
| Present |
79 |
54 |
||
| Tubular atrophy / interstitial fibrosis (T) | ||||
| Absent or Mild (0%-25%) |
68 |
0.03 |
57% |
0.8 |
| Moderate (>25%) |
100 |
50% |
||
| Crescent (C) | ||||
| Absent |
62 |
0.002 |
47 |
0.004 |
| Present |
82 |
68 |
||
| Glomerulus necrosis (N) | ||||
| Absent |
69 |
0.6 | 55 |
0.7 |
| Present | 76 | 61 | ||
Abbreviations: RASB, renin angiotensin system blockade.